Keyword: Copaxone

Kickbacks whistleblowers reached their "put up or shut up" moment for producing solid evidence—and didn't, Teva says.

Mylan may have cut the list price on its Copaxone copy, but the Israeli drugmaker says it’s still on track to rake in significant 2018 sales.

Thanks to Mylan’s price cut on generic Copaxone, Teva’s going to have to take the price on its branded product down. And it may be wise to start now.

Mylan has slashed its list price on generic Copaxone, and the move has industry watchers scratching their heads.

Teva's restructuring and cost-cutting initiatives are clearly working, but worries about generic competition to MS blockbuster Copaxone are putting pressure on Teva to continue to innovate.

A recently released FDA document shows that Pfizer's troubled fill-finish plant in Kansas was cited for continuing to repeat mistakes already cited by the FDA.

Novartis’ copycat arm, Sandoz, needed a win. And it got a key one Tuesday with the approval of generic 40-mg Copaxone.

Teva just went through a horrible year, today reporting a $17.5 billion operating loss in 2017, but execs said things will get worse before they get better.

Pfizer reported earnings today, including good news for Sandoz and partner Momenta.

Teva Pharmaceuticals, which has already paid $520 million in the U.S. for having bribed foreign doctors, has now settled with authorities in Israel.